RBC Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)

RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $1,229.00 price target on Regeneron Pharma (NASDAQ: REGN)

The analyst comments "While we think investors generally lean positively on REGN’s commercial and pipeline prospects, our recent conversations lead us to believe that the mid-decade step-up in SNY collaboration revenue is still underappreciated by many. We expect REGN's share not only to step up more than consensus models (+$3B vs. +$2B), but that this will - along with product growth and pipeline developments - create a near-8% operating margin improvement and near-$20/shr (43%) EPS expansion from 2025-2027, rapidly bringing REGN's multiple from in-line to meaningfully discounted vs. high-growth larger biopharma peers. We continue to view REGN as one of the most attractive large-cap biotechs, with potential for further upside on any positive updates on dupi strength/COPD expansion, EyleaHD uptake, and pipeline progress."

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $1053.14 yesterday.

You May Also Be Interested In

• Stifel Upgrades Shopify (SHOP) to Buy: 'realistic path to 30%-plus revenue growth in 2026'
• Tencent In Talks To Become Largest Holder Of Manus, Ft Reports
• Day 7 ALJ Hearing: Prominent Pain Physician Calls State Medical Marijuana System a Ruse